KSI 101
Alternative Names: KSI-101; KSI-501PLatest Information Update: 22 Aug 2024
At a glance
- Originator Kodiak Sciences
- Class Anti-inflammatories; Eye disorder therapies; Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action Interleukin 6 inhibitors; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Retinal oedema